No biomarker
|
Waldenstrom Macroglobulinemia
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
zanubrutinib Sensitive: A1 - Approval
|
zanubrutinib Sensitive: A1 - Approval
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
rituximab + ibrutinib Sensitive: A1 - Approval
|
rituximab + ibrutinib Sensitive: A1 - Approval
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
ibrutinib Sensitive: A1 - Approval
|
ibrutinib Sensitive: A1 - Approval
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
acalabrutinib Sensitive: A2 - Guideline
|
acalabrutinib Sensitive: A2 - Guideline
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
rituximab + ixazomib Sensitive: A2 - Guideline
|
rituximab + ixazomib Sensitive: A2 - Guideline
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
fludarabine oral Sensitive: A2 - Guideline
|
fludarabine oral Sensitive: A2 - Guideline
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
rituximab Sensitive: A2 - Guideline
|
rituximab Sensitive: A2 - Guideline
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
cladribine Sensitive: A2 - Guideline
|
cladribine Sensitive: A2 - Guideline
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
rituximab + bortezomib Sensitive: A2 - Guideline
|
rituximab + bortezomib Sensitive: A2 - Guideline
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
everolimus Sensitive: A2 - Guideline
|
everolimus Sensitive: A2 - Guideline
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
bortezomib Sensitive: A2 - Guideline
|
bortezomib Sensitive: A2 - Guideline
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
ofatumumab Sensitive: A2 - Guideline
|
ofatumumab Sensitive: A2 - Guideline
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
R-CHOP Sensitive: A2 - Guideline
|
R-CHOP Sensitive: A2 - Guideline
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
IRd Sensitive: A2 - Guideline
|
IRd Sensitive: A2 - Guideline
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
FCR Sensitive: A2 - Guideline
|
FCR Sensitive: A2 - Guideline
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
bortezomib + dexamethasone Sensitive: A2 - Guideline
|
bortezomib + dexamethasone Sensitive: A2 - Guideline
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
bendamustine Sensitive: A2 - Guideline
|
bendamustine Sensitive: A2 - Guideline
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
BDR Sensitive: A2 - Guideline
|
BDR Sensitive: A2 - Guideline
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
BR Sensitive: A2 - Guideline
|
BR Sensitive: A2 - Guideline
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
CaRD Sensitive: A2 - Guideline
|
CaRD Sensitive: A2 - Guideline
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
RCD Sensitive: A2 - Guideline
|
RCD Sensitive: A2 - Guideline
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
RCP Sensitive: A2 - Guideline
|
RCP Sensitive: A2 - Guideline
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
venetoclax Sensitive: A2 - Guideline
|
venetoclax Sensitive: A2 - Guideline
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
No biomarker
|
Waldenstrom Macroglobulinemia
|
CLR 131 Sensitive: B - Late Trials
|
CLR 131 Sensitive: B - Late Trials
|
MYD88 L265P
|
Waldenstrom Macroglobulinemia
|
MYD88 L265P
|
Waldenstrom Macroglobulinemia
|
zanubrutinib Sensitive: B - Late Trials
|
zanubrutinib Sensitive: B - Late Trials
|
MYD88 wild-type
|
Waldenstrom Macroglobulinemia
|
MYD88 wild-type
|
Waldenstrom Macroglobulinemia
|
zanubrutinib Sensitive: B - Late Trials
|
zanubrutinib Sensitive: B - Late Trials
|
MYD88 mutation
|
Waldenstrom Macroglobulinemia
|
MYD88 mutation
|
Waldenstrom Macroglobulinemia
|
zanubrutinib Sensitive: B - Late Trials
|
zanubrutinib Sensitive: B - Late Trials
|
CXCR4 mutation
|
Waldenstrom Macroglobulinemia
|
CXCR4 mutation
|
Waldenstrom Macroglobulinemia
|
rituximab + ixazomib Sensitive: C2 – Inclusion Criteria
|
rituximab + ixazomib Sensitive: C2 – Inclusion Criteria
|
MYD88 L265P
|
Waldenstrom Macroglobulinemia
|
MYD88 L265P
|
Waldenstrom Macroglobulinemia
|
rituximab + ixazomib Sensitive: C2 – Inclusion Criteria
|
rituximab + ixazomib Sensitive: C2 – Inclusion Criteria
|
CXCR4 mutation
|
Waldenstrom Macroglobulinemia
|
CXCR4 mutation
|
Waldenstrom Macroglobulinemia
|
venetoclax Sensitive: C2 – Inclusion Criteria
|
venetoclax Sensitive: C2 – Inclusion Criteria
|
CXCR4 mutation
|
Waldenstrom Macroglobulinemia
|
CXCR4 mutation
|
Waldenstrom Macroglobulinemia
|
BDR Sensitive: C3 – Early Trials
|
BDR Sensitive: C3 – Early Trials
|
MYD88 mutation
|
Waldenstrom Macroglobulinemia
|
MYD88 mutation
|
Waldenstrom Macroglobulinemia
|
ibrutinib Sensitive: C3 – Early Trials
|
ibrutinib Sensitive: C3 – Early Trials
|
CXCR4 mutation
|
Waldenstrom Macroglobulinemia
|
CXCR4 mutation
|
Waldenstrom Macroglobulinemia
|
ibrutinib Sensitive: C3 – Early Trials
|
ibrutinib Sensitive: C3 – Early Trials
|
CXCR4 mutation
|
Waldenstrom Macroglobulinemia
|
CXCR4 mutation
|
Waldenstrom Macroglobulinemia
|
rituximab Sensitive: C3 – Early Trials
|
rituximab Sensitive: C3 – Early Trials
|
CXCR4 G336X
|
Waldenstrom Macroglobulinemia
|
CXCR4 G336X
|
Waldenstrom Macroglobulinemia
|
rituximab + ixazomib Sensitive: C3 – Early Trials
|
rituximab + ixazomib Sensitive: C3 – Early Trials
|
CXCR4 S338X
|
Waldenstrom Macroglobulinemia
|
CXCR4 S338X
|
Waldenstrom Macroglobulinemia
|
rituximab + ixazomib Sensitive: C3 – Early Trials
|
rituximab + ixazomib Sensitive: C3 – Early Trials
|
CXCR4 H350fs*
|
Waldenstrom Macroglobulinemia
|
CXCR4 H350fs*
|
Waldenstrom Macroglobulinemia
|
rituximab + ixazomib Sensitive: C3 – Early Trials
|
rituximab + ixazomib Sensitive: C3 – Early Trials
|
CXCR4 S338X + TP53 R196X
|
Waldenstrom Macroglobulinemia
|
CXCR4 S338X + TP53 R196X
|
Waldenstrom Macroglobulinemia
|
rituximab + ixazomib Sensitive: C3 – Early Trials
|
rituximab + ixazomib Sensitive: C3 – Early Trials
|
CXCR4 K327fs*
|
Waldenstrom Macroglobulinemia
|
CXCR4 K327fs*
|
Waldenstrom Macroglobulinemia
|
rituximab + ixazomib Sensitive: C3 – Early Trials
|
rituximab + ixazomib Sensitive: C3 – Early Trials
|
CXCR4 R338X
|
Waldenstrom Macroglobulinemia
|
CXCR4 R338X
|
Waldenstrom Macroglobulinemia
|
rituximab + ixazomib Sensitive: C3 – Early Trials
|
rituximab + ixazomib Sensitive: C3 – Early Trials
|
CXCR4 T318fs*
|
Waldenstrom Macroglobulinemia
|
CXCR4 T318fs*
|
Waldenstrom Macroglobulinemia
|
rituximab + ixazomib Sensitive: C3 – Early Trials
|
rituximab + ixazomib Sensitive: C3 – Early Trials
|
CXCR4 L326fs*
|
Waldenstrom Macroglobulinemia
|
CXCR4 L326fs*
|
Waldenstrom Macroglobulinemia
|
rituximab + ixazomib Sensitive: C3 – Early Trials
|
rituximab + ixazomib Sensitive: C3 – Early Trials
|
CXCR4 S347fs*
|
Waldenstrom Macroglobulinemia
|
CXCR4 S347fs*
|
Waldenstrom Macroglobulinemia
|
rituximab + ixazomib Sensitive: C3 – Early Trials
|
rituximab + ixazomib Sensitive: C3 – Early Trials
|
MYD88 L265P + CXCR4 mutation
|
Waldenstrom Macroglobulinemia
|
MYD88 L265P + CXCR4 mutation
|
Waldenstrom Macroglobulinemia
|
venetoclax Resistant: C3 – Early Trials
|
venetoclax Resistant: C3 – Early Trials
|
MYD88 L265P
|
Waldenstrom Macroglobulinemia
|
MYD88 L265P
|
Waldenstrom Macroglobulinemia
|
venetoclax Sensitive: C3 – Early Trials
|
venetoclax Sensitive: C3 – Early Trials
|
CD38 expression
|
Waldenstrom Macroglobulinemia
|
CD38 expression
|
Waldenstrom Macroglobulinemia
|
daratumumab Sensitive: C3 – Early Trials
|
daratumumab Sensitive: C3 – Early Trials
|
MYD88 L265P
|
Waldenstrom Macroglobulinemia
|
MYD88 L265P
|
Waldenstrom Macroglobulinemia
|
daratumumab Sensitive: C3 – Early Trials
|
daratumumab Sensitive: C3 – Early Trials
|
CXCR4 mutation
|
Waldenstrom Macroglobulinemia
|
CXCR4 mutation
|
Waldenstrom Macroglobulinemia
|
daratumumab Sensitive: C3 – Early Trials
|
daratumumab Sensitive: C3 – Early Trials
|
MYD88 mutation + CXCR4 mutation
|
Waldenstrom Macroglobulinemia
|
MYD88 mutation + CXCR4 mutation
|
Waldenstrom Macroglobulinemia
|
ibrutinib Sensitive: C3 – Early Trials
|
ibrutinib Sensitive: C3 – Early Trials
|
CXCR4 mutation
|
Waldenstrom Macroglobulinemia
|
CXCR4 mutation
|
Waldenstrom Macroglobulinemia
|
ibrutinib + X4P-001 Sensitive: C3 – Early Trials
|
ibrutinib + X4P-001 Sensitive: C3 – Early Trials
|
MYD88 L265P
|
Waldenstrom Macroglobulinemia
|
MYD88 L265P
|
Waldenstrom Macroglobulinemia
|
X4P-001 Sensitive: C3 – Early Trials
|
X4P-001 Sensitive: C3 – Early Trials
|
CXCR4 mutation
|
Waldenstrom Macroglobulinemia
|
CXCR4 mutation
|
Waldenstrom Macroglobulinemia
|
ibrutinib + BMS-936564 Sensitive: C3 – Early Trials
|
ibrutinib + BMS-936564 Sensitive: C3 – Early Trials
|
MYD88 L265P
|
Waldenstrom Macroglobulinemia
|
MYD88 L265P
|
Waldenstrom Macroglobulinemia
|
orelabrutinib Sensitive: C3 – Early Trials
|
orelabrutinib Sensitive: C3 – Early Trials
|
MYD88 mutation + CXCR4 mutation
|
Waldenstrom Macroglobulinemia
|
MYD88 mutation + CXCR4 mutation
|
Waldenstrom Macroglobulinemia
|
ibrutinib + X4P-001 Sensitive: C3 – Early Trials
|
ibrutinib + X4P-001 Sensitive: C3 – Early Trials
|
MYD88 mutation
|
Waldenstrom Macroglobulinemia
|
MYD88 mutation
|
Waldenstrom Macroglobulinemia
|
rituximab Sensitive: C4 – Case Studies
|
rituximab Sensitive: C4 – Case Studies
|